Tags : CAR-T Cell Therapy

Kite Reports Submission of BLA to the US FDA for

Shots: The Kite has submitted BLA to the US FDA for its investigational CAR T cell therapy, KTE-X19 for the treatment of r/r MCL The BLA submission is based on P-II ZUMA-2 study assessing KTE-X19 in 74 patients aged ≥18 yrs. with r/r MCL prior treated with up to 5L therapies, demonstrating ORR (93%); CR […]Read More

Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine

Shots: Novartis to get royalty-free worldwide, intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing process, and Novartis will undertake distribution, regulatory and commercialization in China Novartis to pay $40M in the form of equity purchase for its 1,458,257 shares […]Read More